Clinical trials
Phase 2 Ulcer trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Recruiting | 5 |
| Unknown status | 4 |
| Terminated | 4 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Suspended | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cumberland Pharmaceuticals | 2 |
| Instituto Nacional de Cancer, Brazil | 2 |
| OcuNexus Therapeutics, Inc. | 2 |
| PluroGen Therapeutics, Inc | 2 |
| Allergan | 1 |
| AnGes USA, Inc. | 1 |
| Arava Bio Tech Ltd. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Athos Therapeutics Inc | 1 |
| Barwon Health | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ulcer | 46 |
| Stomatitis | 9 |
| Diabetic Foot | 8 |
| Wounds and Injuries | 8 |
| Colitis, Ulcerative | 6 |
| Colitis | 5 |
| Varicose Ulcer | 5 |
| Diabetes Mellitus | 4 |
| Infections | 4 |
| Burns | 3 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.